Bailard Inc. Sells 400 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Bailard Inc. reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 34.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 750 shares of the company’s stock after selling 400 shares during the period. Bailard Inc.’s holdings in Medpace were worth $230,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Miller Howard Investments Inc. NY grew its stake in Medpace by 1.3% in the fourth quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock worth $943,000 after purchasing an additional 39 shares during the period. Schulhoff & Co. Inc. increased its stake in shares of Medpace by 2.0% in the 3rd quarter. Schulhoff & Co. Inc. now owns 2,250 shares of the company’s stock worth $545,000 after acquiring an additional 45 shares in the last quarter. Campbell Newman Asset Management Inc. increased its stake in shares of Medpace by 0.4% in the 4th quarter. Campbell Newman Asset Management Inc. now owns 11,095 shares of the company’s stock worth $3,401,000 after acquiring an additional 46 shares in the last quarter. Treasurer of the State of North Carolina lifted its position in Medpace by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company’s stock valued at $2,477,000 after acquiring an additional 50 shares during the period. Finally, Sectoral Asset Management Inc. boosted its stake in Medpace by 4.9% during the third quarter. Sectoral Asset Management Inc. now owns 1,181 shares of the company’s stock worth $286,000 after acquiring an additional 55 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Medpace Investors, Llc sold 13,988 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the completion of the sale, the insider now owns 5,525,959 shares of the company’s stock, valued at approximately $2,135,175,298.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the transaction, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the sale, the insider now directly owns 5,525,959 shares of the company’s stock, valued at approximately $2,135,175,298.01. The disclosure for this sale can be found here. Over the last three months, insiders have sold 189,340 shares of company stock valued at $76,651,647. Insiders own 20.30% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $400.21 on Tuesday. Medpace Holdings, Inc. has a 1 year low of $197.39 and a 1 year high of $421.00. The company has a market cap of $12.40 billion, a P/E ratio of 40.80, a PEG ratio of 1.97 and a beta of 1.38. The stock’s fifty day moving average price is $398.00 and its 200-day moving average price is $327.40.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.75. The firm had revenue of $511.00 million during the quarter, compared to analysts’ expectations of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm’s quarterly revenue was up 17.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.27 earnings per share. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MEDP shares. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and boosted their price target for the stock from $340.00 to $450.00 in a research report on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 target price on the stock. Guggenheim raised their price target on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and increased their price objective for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Finally, StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.